4.4000 +0.40 (10.00%)
Pre-Market: 8:47AM EDT
|Bid||3.7500 x 1000|
|Ask||0.0000 x 900|
|Day's Range||3.8000 - 4.0250|
|52 Week Range||3.2550 - 11.8100|
|Beta (3Y Monthly)||0.25|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||17.75|
RESEARCH TRIANGLE PARK, N.C., June 19, 2019 -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management.
Targeting New Drug Application to U.S. FDA for PEDMARKTM in late 2019 to early 2020Strong financial position with $20.2 million in cash and no debt RESEARCH TRIANGLE PARK,.
As one Triangle public company rapidly approaches FDA approval of its only lead drug, its executives say the company is set up for the potential – and expectation – of buy-out opportunities.
Despite a delay in the commercial launch of the company's only lead candidate, Fennec's (Nasdaq: FENC) executives continue to see an uptick in their annual compensation.
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC): Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product...
Initiated rolling New Drug Application to U.S. FDA for PEDMARKTMSecured $12. 5 million debt financing to support a potential commercial launch Strong financial position with.
The U.S. operating subsidiary of Fennec Pharmaceuticals Inc. entered into a Loan and Security Agreement with Bridge Bank, securing a $12.5 million debt facility with a maturity date of October 1, 2023, which will be funded upon New Drug Application (NDA) approval of PEDMARKTM in the U.S. The Company intends to use the proceeds from the loan to provide working capital for commercialization activities for PEDMARKTM upon NDA approval. “We welcome the commitment of Bridge Bank to Fennec as this debt facility provides us with the option to access minimally dilutive capital at an attractive cost upon NDA approval.
A look at the shareholders of Fennec Pharmaceuticals Inc. (NASDAQ:FENC) can tell us which group is most powerful. Insiders often own a large chunk of younger, smaller, companies while huge Read More...
CORAL GABLES, FL / ACCESSWIRE / December 20, 2018 / The biotech industry is predicated on the notion that, presently, we can do more to create better treatment options and medical technologies to improve the quality of care for those suffering from a myriad of ailments. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Fennec Pharmaceuticals, Inc (FENC), Aimmune Therapeutics, Inc (AIMT), and Kezar Life Sciences, Inc (KZR) are 4 biotech stocks representing companies working towards the advancement of the biotech sector. Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company ready to meet the demands of consumers looking for access to quality primary care.
PEDMARKTM is proposed to be indicated for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to
RESEARCH TRIANGLE PARK, N.C., Nov. 16, 2018 -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM.
Positive Opinion on the Pediatric Investigation Plan from EMA for PEDMARKTMTargeting US approval of PEDMARKTM in the second half of 2019Strong financial position with $24.5.